Overview
- J&J and Halda signed a definitive agreement for a $3.05 billion all-cash acquisition, with closing expected in the next few months.
- Johnson & Johnson said the transaction will lower its adjusted 2026 earnings per share by $0.15 due to short-term financing and employee equity charges.
- Halda’s lead asset HLD-0915 is an oral, once-daily RIPTAC therapy in Phase I/II for metastatic castration-resistant prostate cancer.
- Early clinical data showed encouraging activity, including PSA declines and RECIST partial responses in heavily pretreated patients.
- The purchase transfers Halda’s broader RIPTAC pipeline for solid tumors such as breast and lung cancer, which J&J views as a platform with potential beyond oncology.